PCA
ONCY

Prosperity Capital Advisors’s Oncolytics Biotech ONCY Stock Holding History

Prosperity Capital Advisors’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,000
Closed -$11.6K – 426
2025
Q2 		$11.6K Hold
15,000
– – ﹤0.01% 381
2025
Q1 		$7.91K Hold
15,000
– – ﹤0.01% 349
2024
Q4 		$13.7K Hold
15,000
– – ﹤0.01% 337
2024
Q3 		$13.1K Hold
15,000
– – ﹤0.01% 336
2024
Q2 		$14.8K Hold
15,000
– – ﹤0.01% 308
2024
Q1 		$15.9K Hold
15,000
– – ﹤0.01% 322
2023
Q4 		$20.3K Buy
+15,000
New +$23.4K ﹤0.01% 258

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Prosperity Capital Advisors's ONCY Position: Q3 2025 in Review

Prosperity Capital Advisors sold out of Oncolytics Biotech (ONCY) in Q3 2025, closing a stake of 15,000 shares — an estimated $11.6K sold.

Prosperity Capital Advisors first reported a position in ONCY in Q4 2023 and held it in 7 quarters. The position peaked at $20.3K in Q4 2023. 56 funds tracked by Wall St. Rank hold ONCY as of Q3 2025.

  • Prosperity Capital Advisors reported no remaining Oncolytics Biotech position as of Q3 2025 after selling out during the quarter.
  • Prosperity Capital Advisors sold 15,000 Oncolytics Biotech shares in Q3 2025, an estimated $11.6K.
  • Prosperity Capital Advisors first reported a position in Oncolytics Biotech in Q4 2023 and held it in 7 quarters.
  • Prosperity Capital Advisors's Oncolytics Biotech position peaked at $20.3K in Q4 2023.
  • 56 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2025.

Based on Prosperity Capital Advisors's 13F filing for Q3 2025, filed 21 Oct 2025.